The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits resistant NTRK kinase domain mutants Meeting Abstract
| Authors: | Drilon, A.; Hofmann, N.; Flynn, D.; Smith, B.; Davare, M. |
| Abstract Title: | The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits resistant NTRK kinase domain mutants |
| Meeting Title: | 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 69 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2016 Nov 29-Dec 2 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2016-12-01 |
| Start Page: | S138 |
| Language: | English |
| ACCESSION: | WOS:000390503500405 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(16)33010-6 |
| Notes: | Meeting Abstract: 422 -- 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 29-DEC 02, 2016 -- Munich, GERMANY -- Source: Wos |
